-transparent.png){kind=logo}
The influence of two progestins, medroxyprogesterone acetate (MPA) and megestrol acetate (MA), given orally in high doses, on the pharmacokinetics of antipyrine, digitoxin, and warfarin were studied in patients with advanced breast cancer. Antipyrine and warfarin were given as a single test dose before and after 5 weeks of progestin treatment. The pharmacokinetics of digitoxin was investigated at steady state in patients receiving this drug therapeutically before and during treatment with progestins. Small changes in clearance rates for antipyrine, warfarin, and digitoxin were found. A minor decrease observed in warfarin clearance however may be of clinical importance. Half-lives decreased by 13% for antipyrine and increased by 71% for warfarin. High-dose progestins given orally do not seem to have a major influence on drug metabolism, probably reflecting a minor effect on drug and steroid-metabolizing microsomal mono-oxygenases in the liver.
S Lundgren, and
S Kvinnsland, and
E Utaaker, and
O Bakke, and
P M Ueland
December 1984,
Clinical pharmacology and therapeutics,
S Lundgren, and
S Kvinnsland, and
E Utaaker, and
O Bakke, and
P M Ueland
December 1981,
Clinical pharmacology and therapeutics,
S Lundgren, and
S Kvinnsland, and
E Utaaker, and
O Bakke, and
P M Ueland
December 1990,
Seminars in oncology,
S Lundgren, and
S Kvinnsland, and
E Utaaker, and
O Bakke, and
P M Ueland
January 1981,
Acta obstetricia et gynecologica Scandinavica. Supplement,
S Lundgren, and
S Kvinnsland, and
E Utaaker, and
O Bakke, and
P M Ueland
November 1977,
Cancer research,
S Lundgren, and
S Kvinnsland, and
E Utaaker, and
O Bakke, and
P M Ueland
December 1987,
Cancer treatment reports,
S Lundgren, and
S Kvinnsland, and
E Utaaker, and
O Bakke, and
P M Ueland
June 1984,
Australian and New Zealand journal of medicine,
S Lundgren, and
S Kvinnsland, and
E Utaaker, and
O Bakke, and
P M Ueland
January 1986,
Cancer chemotherapy and pharmacology,
S Lundgren, and
S Kvinnsland, and
E Utaaker, and
O Bakke, and
P M Ueland
March 1990,
Biopharmaceutics & drug disposition,
S Lundgren, and
S Kvinnsland, and
E Utaaker, and
O Bakke, and
P M Ueland
December 2021,
Breast (Edinburgh, Scotland),
